BioWorld

Jan. 29, 2009

Exact to Get $24.5M in Deal with Genzyme

After rejecting a hostile bid by Sequenom Inc., Exact Sciences Corp. has entered a $24.5 million deal with Genzyme Corp. in a move that could help grow Exact's cancer diagnostics business. (BioWorld Today) Read More

Seattle Genetics Braves Public Market to Price $55.8M Offering

Two Studies Report on Models, Consequences of Hepatitis C

Gilead has Strong 4Q, but U.S. HIV Drug Sales Down

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Businesswoman pressing dollar sign on touchscreen

JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

BioWorld

It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...